Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.
Kurth K, Tunn U, Ay R, Schröder FH, Pavone-Macaluso M, Debruyne F, ten Kate F, de Pauw M, Sylvester R. Kurth K, et al. Among authors: sylvester r. J Urol. 1997 Aug;158(2):378-84. doi: 10.1016/s0022-5347(01)64484-7. J Urol. 1997. PMID: 9224307 Clinical Trial.
Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European organization for research on treatment of cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organization for Research on Treatment of Cancer Genitourinary Group.
Bouffioux C, Denis L, Oosterlinck W, Viggiano G, Vergison B, Keuppens F, De Pauw M, Sylvester R, Cheuvart B. Bouffioux C, et al. Among authors: sylvester r. J Urol. 1992 Aug;148(2 Pt 1):297-301. doi: 10.1016/s0022-5347(17)36577-1. J Urol. 1992. PMID: 1635122 Clinical Trial.
Long-term follow-up in superficial transitional cell carcinoma of the bladder: prognostic factors for time to first recurrence, recurrence rate, and survival. Final results of a randomized trial comparing doxorubicin hydrochloride, ethoglucid, and transurethral resection alone. EORTC Genitourinary Tract Cancer Cooperative Group.
Kurth K, Schroeder FH, Debruyne F, Senge T, Pavone-Macaluso M, de Pauw M, ten Kate F, Sylvester R. Kurth K, et al. Among authors: sylvester r. Prog Clin Biol Res. 1989;303:481-90. Prog Clin Biol Res. 1989. PMID: 2675005 Clinical Trial. No abstract available.
Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group.
Newling DW, Robinson MR, Smith PH, Byar D, Lockwood R, Stevens I, De Pauw M, Sylvester R. Newling DW, et al. Among authors: sylvester r. Eur Urol. 1995;27(2):110-6. doi: 10.1159/000475139. Eur Urol. 1995. PMID: 7744151 Clinical Trial.
Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865).
Newling DW, Fossa SD, Tunn UW, Kurth KH, de Pauw M, Sylvester R. Newling DW, et al. Among authors: sylvester r. J Urol. 1993 Dec;150(6):1840-4. doi: 10.1016/s0022-5347(17)35911-6. J Urol. 1993. PMID: 8230517 Clinical Trial.
A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder.
Oosterlinck W, Kurth KH, Schröder F, Bultinck J, Hammond B, Sylvester R. Oosterlinck W, et al. Among authors: sylvester r. J Urol. 1993 Apr;149(4):749-52. doi: 10.1016/s0022-5347(17)36198-0. J Urol. 1993. PMID: 8455236 Clinical Trial.
500 results